Auris Medical Holding AG (EARS) Reaches $0.28 52 Week Low; Coho Partners LTD Lowered Its Amerisourcebergen Corp. (ABC) Position

February 9, 2018 - By Nellie Frank

The stock of Auris Medical Holding AG (NASDAQ:EARS) hit a new 52-week low and has $0.25 target or 8.00% below today’s $0.28 share price. The 6 months bearish chart indicates high risk for the $16.87 million company. The 1-year low was reported on Feb, 9 by Barchart.com. If the $0.25 price target is reached, the company will be worth $1.35 million less. The stock decreased 11.06% or $0.0343 during the last trading session, reaching $0.2757. About 897,534 shares traded. Auris Medical Holding AG (NASDAQ:EARS) has declined 79.78% since February 9, 2017 and is downtrending. It has underperformed by 96.48% the S&P500.

Coho Partners Ltd decreased Amerisourcebergen Corp. (ABC) stake by 7.53% reported in 2017Q3 SEC filing. Coho Partners Ltd sold 99,766 shares as Amerisourcebergen Corp. (ABC)’s stock declined 1.76%. The Coho Partners Ltd holds 1.22M shares with $101.36 million value, down from 1.32M last quarter. Amerisourcebergen Corp. now has $19.49 billion valuation. The stock decreased 2.59% or $2.37 during the last trading session, reaching $89.18. About 2.09M shares traded or 12.90% up from the average. AmerisourceBergen Corporation (NYSE:ABC) has risen 18.80% since February 9, 2017 and is uptrending. It has outperformed by 2.10% the S&P500.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company has market cap of $16.87 million. The Company’s product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. It currently has negative earnings. The firm is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123.

Among 3 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Auris Medical Holding AG has $8 highest and $4.5000 lowest target. $5.83’s average target is 2014.62% above currents $0.2757 stock price. Auris Medical Holding AG had 4 analyst reports since March 15, 2016 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Friday, June 30. The stock has “Buy” rating by Needham on Friday, August 19. The firm has “Buy” rating given on Tuesday, March 15 by Jefferies.

Among 20 analysts covering AmerisourceBergen (NYSE:ABC), 11 have Buy rating, 0 Sell and 9 Hold. Therefore 55% are positive. AmerisourceBergen had 69 analyst reports since July 27, 2015 according to SRatingsIntel. Robert W. Baird maintained AmerisourceBergen Corporation (NYSE:ABC) rating on Monday, November 6. Robert W. Baird has “Buy” rating and $96.0 target. The firm earned “Hold” rating on Tuesday, February 6 by Mizuho. Cowen & Co upgraded the stock to “Outperform” rating in Tuesday, October 10 report. Mizuho maintained the stock with “Hold” rating in Tuesday, May 30 report. UBS maintained AmerisourceBergen Corporation (NYSE:ABC) rating on Friday, February 5. UBS has “Buy” rating and $110 target. The firm earned “Buy” rating on Tuesday, April 4 by Needham. The firm earned “Buy” rating on Friday, December 15 by Goldman Sachs. On Thursday, February 8 the stock rating was maintained by Needham with “Buy”. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, November 17. The firm earned “Mkt Perform” rating on Friday, May 6 by FBR Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts